Roivant Sciences Ltd. (ROIV)
Largest Insider Buys in Sector
ROIV Stock Price History Chart
ROIV Stock Performance
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Insider Activity of Roivant Sciences Ltd.
Over the last 12 months, insiders at Roivant Sciences Ltd. have bought $0 and sold $136.46M worth of Roivant Sciences Ltd. stock.
On average, over the past 5 years, insiders at Roivant Sciences Ltd. have bought $40.28M and sold $531.15M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 8,000,000 shares for transaction amount of $40M was made by Dexcel Pharma Technologies Ltd. (director) on 2022‑11‑10.
List of Insider Buy and Sell Transactions, Roivant Sciences Ltd.
| 2024-12-18 | Sale | Pres&Chief Investment Officer | 412,584 0.0583% | $12.05 | $4.97M | 0.00% | ||
| 2024-11-20 | Sale | President & COO | 100,000 0.0136% | $11.32 | $1.13M | +5.48% | ||
| 2024-10-21 | Sale | President & COO | 100,000 0.0136% | $11.65 | $1.17M | +2.54% | ||
| 2024-09-26 | Sale | Director by Deputization | 876,000 0.1177% | $11.82 | $10.35M | -2.12% | ||
| 2024-09-26 | Sale | director | 876,000 0.1177% | $11.82 | $10.35M | -2.12% | ||
| 2024-09-25 | Sale | Director by Deputization | 50,000 0.0067% | $11.77 | $588,500 | -1.70% | ||
| 2024-09-25 | Sale | director | 1.41M 0.1881% | $11.77 | $16.56M | -1.66% | ||
| 2024-09-25 | Sale | director | 134,948 0.018% | $11.77 | $1.59M | -1.66% | ||
| 2024-09-24 | Sale | director | 2.14M 0.2831% | $11.63 | $24.91M | -0.47% | ||
| 2024-09-24 | Sale | director | 368,052 0.0486% | $11.63 | $4.28M | -0.47% | ||
| 2024-09-23 | Sale | CEO | 1.98M 0.2657% | $11.79 | $23.38M | -0.50% | ||
| 2024-09-23 | Sale | Chief Accounting Officer | 250,000 0.0338% | $11.89 | $2.97M | -0.50% | ||
| 2024-02-09 | Sale | President & COO | 96,950 0.0129% | $10.92 | $1.06M | +5.18% | ||
| 2024-01-02 | Sale | 10 percent owner | 3M 0.3648% | $11.05 | $33.15M | -0.40% | ||
| 2023-10-05 | Sale | Chief Operating Officer | 153,027 0.0189% | $10.11 | $1.55M | +3.84% | ||
| 2023-10-03 | Sale | Chief Operating Officer | 606,221 0.0758% | $10.25 | $6.21M | +3.74% | ||
| 2023-10-02 | Sale | Chief Operating Officer | 440,752 0.0581% | $10.80 | $4.76M | +2.71% | ||
| 2023-09-28 | Sale | 10 percent owner | 10M 1.2883% | $12.60 | $126M | -13.94% | ||
| 2023-09-28 | Sale | 10 percent owner | 8.44M 0.9967% | $11.55 | $97.48M | -13.94% | ||
| 2023-09-28 | Sale | director | 6.9M 0.8144% | $11.55 | $79.65M | -13.94% |
Insider Historical Profitability
| Dexcel Pharma Technologies Ltd. | director | 102849443 14.1286% | $11.57 | 3 | 0 | +38.38% |
| Oren Dan | 98840843 13.578% | $11.57 | 1 | 0 | +22.38% |
Institutional Investor Ownership
| SoftBank Investment Advisers | $769.75M | 9.89 | 73.03M | 0% | +$0 | 7.6 | |
| Viking Global Investors | $731.15M | 9.39 | 69.37M | 0% | +$0 | 0.26 | |
| QVT Financial | $703.23M | 9.03 | 66.72M | -40.72% | -$482.96M | 70.06 | |
| BlackRock | $381.42M | 4.9 | 36.19M | +73.93% | +$162.13M | 0.01 | |
| Morgan Stanley | $375.6M | 4.82 | 35.64M | +62.52% | +$144.49M | 0.03 |